Back to search

Article

GPNMB overexpression- a marker of resistance to CDK4/6 inhibitors

2026-03-07

Abstract excerpt

<h4>ABSTRACT</h4> Resistance to cyclin-dependent kinase 4/6 inhibitors remains a major clinical challenge in treating estrogen receptor-positive breast cancer, with no reliable predictive biomarkers currently available for patient selection. To investigate resistance mechanisms, we generated drug-tolerant persisters (DTPs) to abemaciclib and palbociclib in a panel of estrogen receptor-positive breast cancer cell...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
89848a87-3cea-5d0e-8ec2-0732acd4650d
DOI
10.64898/2026.03.04.709413
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
GPNMB overexpression- a marker of resistance to CDK4/6 inhibitorsDOI 10.64898/2026.03.04.709413
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer CellsSemantic proximity
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesSemantic proximity
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seqSemantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and TranscriptomicsSemantic proximity
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.Semantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Semantic proximity
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity
Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast CancerSemantic proximity
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity
Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.